Etavopivat

Product Information

Scientific name: Etavopivat (FT-4202)
Brand name: Ν/Α
RESPONSIBLE: Novo Nordisk

Clinical Trial/Study Information

^{Last update: 22/6/2023}

Trial Name: HIBISCUS
Code: NCT04624659
Phase: 2/3
Eligible patient diagnosis: : SCD (adolescent & adults) (age 12-65)
No. of Patients enrolled: : 344 [anticipated] (Last update: 15/2/2023)
Study Sites: 87 Sites per country

Anticipated completion date: December 2026
Scope of the Study / Aim: Increase haemoglobin; decrease annual VOCs

Regulatory Information

Status: Not Authorised

Additional notable points:

• EMA: N/A
• FDA: Orphan drug designation (2020)
• MHRA: N/A